Kamar Nassim, Rostaing Lionel, Alric Laurent, Peron Jean-Marie, Izopet Jacques
CHU de Toulouse, hôpital Rangueil, département de néphrologie et transplantation d'organes, 31059 Toulouse cedex 9, France; Université Paul-Sabatier, 31062 Toulouse, France; Inserm U1043, IFR-BMT, hôpital Purpan, 31059 Toulouse cedex 9, France.
CHU de Toulouse, hôpital Rangueil, département de néphrologie et transplantation d'organes, 31059 Toulouse cedex 9, France; Université Paul-Sabatier, 31062 Toulouse, France; Inserm U1043, IFR-BMT, hôpital Purpan, 31059 Toulouse cedex 9, France.
Presse Med. 2015 Mar;44(3):339-42. doi: 10.1016/j.lpm.2014.10.011. Epub 2015 Jan 29.
The reduction of immunosuppressive therapy is the first-line therapeutic option in transplant-patients with chronic hepatitis E virus infection. Pegylated-interferon has been used for treating hepatitis E virus infection. Ribavirin alone is the treatment of choice of hepatitis E virus infection. Ribavirin is efficient for treating chronic hepatitis E in transplant patients, HIV patients, and hematology patients receiving or not chemotherapy. Ribavirin should be given to patients presenting hepatitis E virus associated extra-hepatic manifestations. The place of ribavirin therapy at acute phase is yet to be determined.
减少免疫抑制治疗是慢性戊型肝炎病毒感染移植患者的一线治疗选择。聚乙二醇干扰素已用于治疗戊型肝炎病毒感染。单独使用利巴韦林是戊型肝炎病毒感染的首选治疗方法。利巴韦林对治疗移植患者、艾滋病毒患者以及接受或未接受化疗的血液学患者的慢性戊型肝炎有效。对于出现戊型肝炎病毒相关肝外表现的患者应给予利巴韦林治疗。利巴韦林在急性期治疗中的地位尚待确定。
